BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baert L, Manfroi B, Casez O, Sturm N, Huard B. The role of APRIL - A proliferation inducing ligand - In autoimmune diseases and expectations from its targeting. Journal of Autoimmunity 2018;95:179-90. [DOI: 10.1016/j.jaut.2018.10.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Liang ZQ, Tu PC, Ji JJ, Xing QQ, Zhao X. Gu-Ben-Fang-Xiao attenuates allergic airway inflammation by inhibiting BAFF-mediated B cell activation. Biomed Pharmacother 2020;132:110801. [PMID: 33049582 DOI: 10.1016/j.biopha.2020.110801] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Shi F, Xue R, Zhou X, Shen P, Wang S, Yang Y. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol 2021;43:666-73. [PMID: 34519594 DOI: 10.1080/08923973.2021.1973493] [Reference Citation Analysis]
3 Sturm N, Quinterot M, Guyot JP, Righini C, Daamen WF, van Kuppevelt TH, Huard B. Polarized Secretion of APRIL by the Tonsil Epithelium Upon Toll-Like Receptor Stimulation. Front Immunol 2021;12:715724. [PMID: 34484218 DOI: 10.3389/fimmu.2021.715724] [Reference Citation Analysis]
4 Rosales C. Neutrophils at the crossroads of innate and adaptive immunity. J Leukoc Biol 2020;108:377-96. [DOI: 10.1002/jlb.4mir0220-574rr] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 31.0] [Reference Citation Analysis]
5 Wang Y, Xiao S, Xia Y, Wang H. The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies. Clin Rev Allergy Immunol 2021. [PMID: 34542806 DOI: 10.1007/s12016-021-08898-7] [Reference Citation Analysis]
6 Takahara M, Nagato T, Nozaki Y, Kumai T, Katada A, Hayashi T, Harabuchi Y. A proliferation-inducing ligand (APRIL) induced hyper-production of IgA from tonsillar mononuclear cells in patients with IgA nephropathy. Cell Immunol 2019;341:103925. [PMID: 31088610 DOI: 10.1016/j.cellimm.2019.103925] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
7 Yao X, Ren Y, Zhao Q, Chen X, Jiang J, Liu D, Hu P. Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. Eur J Pharm Sci 2021;159:105704. [PMID: 33440243 DOI: 10.1016/j.ejps.2021.105704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Wu F, Gao J, Kang J, Wang X, Niu Q, Liu J, Zhang L. B Cells in Rheumatoid Arthritis:Pathogenic Mechanisms and Treatment Prospects. Front Immunol 2021;12:750753. [PMID: 34650569 DOI: 10.3389/fimmu.2021.750753] [Reference Citation Analysis]
9 Prieto-Peña D, Genre F, Remuzgo-Martínez S, Pulito-Cueto V, Atienza-Mateo B, Llorca J, Sevilla-Pérez B, Ortego-Centeno N, Lera-Gómez L, Leonardo MT, Peñalba A, Narváez J, Martín-Penagos L, Rodrigo E, Miranda-Filloy JA, Caminal-Montero L, Collado P, Pérez JS, de Argila D, Rubio E, Luque ML, Blanco-Madrigal JM, Galíndez-Agirregoikoa E, Gualillo O, Martín J, Castañeda S, Blanco R, González-Gay MA, López-Mejías R. BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis. Sci Rep 2021;11:11510. [PMID: 34075170 DOI: 10.1038/s41598-021-91055-z] [Reference Citation Analysis]
10 Phillips BG, Wang Y, Ambati S, Ma P, Meagher RB. Airways therapy of obstructive sleep apnea dramatically improves aberrant levels of soluble cytokines involved in autoimmune disease. Clin Immunol 2020;221:108601. [PMID: 33017651 DOI: 10.1016/j.clim.2020.108601] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Jackson SW, Davidson A. BAFF inhibition in SLE-Is tolerance restored? Immunol Rev 2019;292:102-19. [PMID: 31562657 DOI: 10.1111/imr.12810] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
12 Pouw JN, Leijten EFA, van Laar JM, Boes M. Revisiting B cell tolerance and autoantibodies in seropositive and seronegative autoimmune rheumatic disease (AIRD). Clin Exp Immunol 2021;203:160-73. [PMID: 33090496 DOI: 10.1111/cei.13542] [Reference Citation Analysis]
13 Tesfa D, Sander B, Lindkvist H, Nilsson C, Kimby E, Hägglund H, Wahlin BE, Klimkowska M, Palmblad J. The role of BAFF and G-CSF for rituximab-induced late-onset neutropenia (LON) in lymphomas. Med Oncol 2021;38:70. [PMID: 34003398 DOI: 10.1007/s12032-021-01516-8] [Reference Citation Analysis]
14 Abramson HN. B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma. Int J Mol Sci 2020;21:E5192. [PMID: 32707894 DOI: 10.3390/ijms21155192] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
15 Marcisz M, Huard B, Lipska AG, Samsonov SA. Further analyses of APRIL/APRIL-Receptor/Glycosaminoglycan interactions by biochemical assays linked to computational studies. Glycobiology 2021:cwab016. [PMID: 33682874 DOI: 10.1093/glycob/cwab016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Czaja AJ. Review article: targeting the B cell activation system in autoimmune hepatitis. Aliment Pharmacol Ther 2021;54:902-22. [PMID: 34506662 DOI: 10.1111/apt.16574] [Reference Citation Analysis]
17 Magliozzi R, Marastoni D, Calabrese M. The BAFF / APRIL system as therapeutic target in multiple sclerosis. Expert Opin Ther Targets 2020;24:1135-45. [PMID: 32900236 DOI: 10.1080/14728222.2020.1821647] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Baker D, Pryce G, James LK, Schmierer K, Giovannoni G. Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis. Eur J Neurol 2019;27:221-8. [DOI: 10.1111/ene.14105] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]